SCHEMBL4512902

SCHEMBL4512902

O=c1[nH]nc2c3cc(-c4ccc[nH]4)ccc3ccn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 17/20 0.47
KDR P35968 2/20 0.44
MAP3K7 O43318 1/20 0.44
JAK2 O60674 1/20 0.44
LTK P29376 2/20 0.40
ALK Q9UM73 2/20 0.40
DYRK1B Q9Y463 2/20 0.40
DAPK3 O43293 1/20 0.40
ABL1 P00519 1/20 0.40
PRKACA P17612 1/20 0.40
LIMK1 P53667 1/20 0.40
ROCK1 Q13464 1/20 0.40
RET P07949 1/20 0.40
MET P08581 1/20 0.40
GRK5 P34947 1/20 0.40
CDK8 P49336 1/20 0.40
RPS6KA3 P51812 1/20 0.40
MST1R Q04912 1/20 0.40
TYRO3 Q06418 1/20 0.40
DYRK1A Q13627 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4509185 0.78 CHEK1 (0.44) CHEK1KDRJAK2LTKALK
SCHEMBL4507799 0.77 LTK (0.40) CHEK1KDRJAK2LTKALK
SCHEMBL4517652 0.77 LTK (0.39) CHEK1KDRLTKALKDYRK1B
SCHEMBL4506161 0.77 CHEK1 (0.47) CHEK1KDRJAK2LTKALK
SCHEMBL4500850 0.77 CHEK1 (0.48) CHEK1KDRLTKALKDYRK1B
SCHEMBL4496917 0.75 CHEK1 (0.47) CHEK1KDRLTKALKDYRK1B
SCHEMBL4517754 0.75 CHEK1 (0.47) CHEK1KDRLTKALKDYRK1B
SCHEMBL4491588 0.75 CHEK1 (0.40) CHEK1KDRLTKALKDYRK1B
SCHEMBL4499252 0.75 CHEK1 (0.47) CHEK1KDRLTKALKDYRK1B
SCHEMBL4496668 0.74 LTK (0.40) CHEK1KDRJAK2LTKALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501435-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-03-10 US disclosed
US-7501435-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-03-10 US disclosed
US-7501435-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-03-10 US disclosed
WO-2007127138-A1 TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-11-08 WO disclosed
US-20070254879-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2007-11-01 US disclosed
US-20070254879-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2007-11-01 US disclosed
US-20070254879-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254879-A1 Inhibitors of checkpoint kinases CHEK1, CHEK2, PLK1 CHEK1 1/4885KDR 2698/4885MAP3K7 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.